Novartis Hopes To Avoid Long FDA Delay For MF59 Adjuvant in Flu Vaccine

Novartis is trying to convince FDA that its squalene vaccine adjuvant MF59 is a non-threatening vaccine component that does not deserve to get caught in a long regulatory review of new vaccine technologies